Effect of neoadjuvant systemic therapy given during window trials on quality metrics in resectable head and neck squamous cell carcinoma.
Marco A. Mascarella(Jewish General Hospital), Umamaheswar Duvvuri(City University of New York), Mark Kubik(UPMC Hillman Cancer Center), Shaum Sridharan(University of Pittsburgh), Varun Vendra(University of Pittsburgh Medical Center), James Ohr(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Moon J. Fenton(University of Tennessee Health Science Center), Seungwon Kim(UPMC Hillman Cancer Center), Dan P. Zandberg(University of Pittsburgh Medical Center)
Cited by 3
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632